Downtrend on the daily chart: below its 50- and 200-day averages · 50-day above the 200-day · SuperTrend down since Sep 18 · below the Ichimoku cloud · RSI 40 · MACD above its signal
None of the 29 investors followed here reported a position in NCEL in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a NCEL trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Apr 26, 2026 | Samuel OlivierDirector | Purchase at price 3.87 per share. | 81.8K | $316.64K |
| Apr 26, 2026 | Revel MichelOfficer, Director and Beneficial Owner | Purchase at price 3.87 per share. | 54.5K | $211.09K |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 36.8 | 11.5 | -26.9 | 108.0 | -20.2 | 4.0 | -4.6 | -6.2 | -6.1 | -7.6 | +49.5% | ||
| 2025 | 18.0 | -26.1 | -16.3 | -4.4 | 49.5 | 31.8 | -36.6 | 15.2 | -13.7 | -60.2 | -45.0 | -52.6 | −91.0% |
| 2024 | -22.0 | -15.9 | -53.5 | -22.2 | 0.7 | 53.9 | 0.9 | -32.0 | -14.9 | -28.4 | -6.9 | -37.6 | −91.1% |
| 2023 | 0.8 | 10.0 | 6.3 | -12.5 | -20.3 | 3.8 | -15.6 | 9.9 | -31.4 | -5.7 | -36.4 | 40.5 | −54.3% |
| 2022 | -18.9 | 32.2 | 18.5 | -39.2 | -20.7 | -13.7 | -37.0 | 33.8 | 25.3 | -15.6 | 58.7 | 55.4 | +16.2% |
| 2021 | -1.0 | 41.3 | -9.4 | -5.7 | -9.0 | -17.2 | -5.0 | 1.2 | -13.6 | -6.0 | -45.3 | −61.6% |
Buy / hold / sell counts
NewcelX Ltd., a biopharmaceutical company, engages in developing transformative stem-cell-derived therapies for Diabetes. The company develops NCEL-101, a cellular therapy product based on enriched pancreatic islet-like clusters for the treatment of Type 1 diabetes and Type 2 insulin dependent diabetes; AstroRx, an off-the-shelf cryopreserved cell therapy product for the treatment of Amyotrophic Lateral Sclerosis and neurodegenerative indications; and Dual Orexin-Receptor Agonist (DOXA), a small molecules platform for the treatment of sleep disorders, Neurodegenerative/ neuroinflammation diseases, and Diabetes Associated Neurological Disorders. It also develops iTOL-102, NCEL-201, NCEL-301, and NCEL-007. NewcelX Ltd. was founded in 2008 and is headquartered in Kloten, Switzerland.